1. Show article details.

    Pfizer and BioNTech Initiate Study to Evaluate Omicron-Based COVID-19 Vaccine in Adults 18 to 55 Years of Age

    GlobeNewswire – 6:45 AM ET 01/25/2022

    NEW YORK and MAINZ, GERMANY, JANUARY 25, 2022 — Pfizer Inc. and BioNTech SE (BNTX) today announced the initiation of a clinical study to evaluate the safety, tolerability and immunogenicity of an Omicron-based vaccine candidate in healthy adults 18 through 55 years of age.

  2. Show article details.

     Pfizer and BioNTech Initiate Study to Evaluate Omicron-Based COVID-19 Vaccine in Adults 18 to 55 Years of Age

    Business Wire – 6:45 AM ET 01/25/2022

     . Pfizer Inc. (PFE) and BioNTech SE (BNTX) today announced the initiation of a clinical study to evaluate the safety, tolerability and immunogenicity of an Omicron-based vaccine candidate in healthy adults 18 through 55 years of age. This press release features multimedia.

  3. Show article details.

    BioNTech and InstaDeep Developed and Successfully Tested Early Warning System to Detect Potential High-Risk SARS-CoV-2 Variants

    GlobeNewswire – 7:00 AM ET 01/11/2022

    MAINZ, Germany and LONDON, United Kingdom, January 11, 2022 — BioNTech SE (BNTX) and InstaDeep Ltd today announced the development of a new computational method that analyses worldwide available sequencing data and predicts high-risk variants of SARS-CoV-2.

  4. Show article details.

    BioNTech and Crescendo Biologics Announce Global Collaboration to Develop Multi-specific Precision Immunotherapies

    GlobeNewswire – 8:00 AM ET 01/10/2022

    MAINZ, Germany and CAMBRIDGE, UK, January 10, 2022 – BioNTech SE (BNTX) and Crescendo Biologics Ltd, a clinical stage immuno-oncology company developing novel, targeted T cell enhancing therapeutics, today announced that they have entered a multi-target discovery collaboration to develop novel immunotherapies for the treatment of patients with cancer and other diseases.

  5. Show article details.

    Pfizer and BioNTech Sign New Global Collaboration Agreement to Develop First mRNA-based Shingles Vaccine

    GlobeNewswire – 6:45 AM ET 01/05/2022

    NEW YORK and MAINZ, Germany, January 5, 2022 — Pfizer Inc. and BioNTech SE (BNTX) today announced a new research, development and commercialization collaboration to develop a potential first mRNA-based vaccine for the prevention of shingles, a debilitating, disfiguring and painful disease that impacts about one in three people in the United States during their lifetime.

  6. Show article details.

    Pfizer and BioNTech Sign New Global Collaboration Agreement to Develop First mRNA-based Shingles Vaccine

    Business Wire – 6:45 AM ET 01/05/2022

    NEW YORK & MAINZ, Germany---- Pfizer Inc. (PFE) and BioNTech SE (BNTX) today announced a new research, development and commercialization collaboration to develop a potential first mRNA-based vaccine for the prevention of shingles, a debilitating, disfiguring and painful disease that impacts about one in three people in the United States during their lifetime. This press release features multimedia.

  7. Show article details.

    Pfizer and BioNTech Receive U.S. FDA Emergency Use Authorization of COVID-19 Vaccine Booster for Individuals 12 Years of Age and Older

    Business Wire – 9:45 AM ET 01/03/2022

    NEW YORK & MAINZ, Germany---- Pfizer Inc. (PFE) and BioNTech SE (BNTX) today announced that the U.S. Food and Drug Administration has expanded the Emergency Use Authorization of a booster dose of the Pfizer-BioNTech COVID-19 Vaccine to include individuals 12 years of age and older. This press release features multimedia.

  8. Show article details.

    BioNTech to Present at the 40th Annual J.P. Morgan Healthcare Conference

    GlobeNewswire – 6:45 AM ET 12/27/2021

    MAINZ, Germany, December 27, 2021 — BioNTech SE (BNTX) announced today that CEO and Co-founder Ugur Sahin, M.D., will present a corporate overview and update at the virtual 40th Annual J.P. Morgan Healthcare Conference on Tuesday, January 11, 2022, at 9:45 am ET.

  9. Show article details.

    Pfizer and BioNTech to Provide European Union More Than 200 Million Additional Doses of COMIRNATY® to Help Meet Continued Need for Vaccine Supply

    Business Wire – 10:05 AM ET 12/20/2021

    NEW YORK & MAINZ, Germany---- Pfizer Inc. (PFE) and BioNTech SE (BNTX) today announced an agreement has been reached with the European Commission and its member states to exercise an option to purchase more than 200 million additional doses of COMIRNATY®, the companies’ COVID-19 vaccine. This press release features multimedia.

  10. Show article details.

    Pfizer and BioNTech Receive U.S. FDA Emergency Use Authorization of COVID-19 Vaccine Booster for Individuals 16 Years and Older

    GlobeNewswire – 12:15 PM ET 12/09/2021

    NEW YORK and MAINZ, Germany, December 9, 2021 — Pfizer Inc. and BioNTech SE (BNTX) today announced that the U.S. Food and Drug Administration has expanded the Emergency Use Authorization of a booster dose of the Pfizer-BioNTech COVID-19 vaccine to include individuals 16 years of age and older.

  11. Show article details.

    Pfizer and BioNTech Receive U.S. FDA Emergency Use Authorization of COVID-19 Vaccine Booster for Individuals 16 Years and Older

    Business Wire – 12:07 PM ET 12/09/2021

    Pfizer Inc. (PFE) and BioNTech SE (BNTX) today announced that the U.S. Food and Drug Administration has expanded the Emergency Use Authorization of a booster dose of the Pfizer-BioNTech COVID-19 Vaccine to include individuals 16 years of age and older. This press release features multimedia.

  12. Show article details.

    Direxion Launches mRNA ETF (MSGR)

    PR Newswire – 8:41 AM ET 12/09/2021

    NEW YORK, Dec. 9, 2021  Direxion announced today the launch of the Direxion mRNA ETF. MSGR invests in companies believed to be at the forefront of the development and application of messenger RNA technology. The MSGR ETF seeks investment results, before fees and expenses, of the BITA Messenger RNA Technology Index. "For years, messenger RNA technologies struggled to gain acceptance.

  13. Show article details.

    BioNTech to Hold Digital Press Conference to Provide an Update on Omicron Variant

    GlobeNewswire – 7:15 AM ET 12/08/2021

    MAINZ, Germany, December 8, 2021 – BioNTech SE (BNTX) will hold a digital press conference on Wednesday, December 8, 2021, to present the results from initial laboratory studies which started about two weeks ago. International digital press conference at 3.00 pm CET / 9.00 am ETPlease register here. The conference can be streamed.

  14. Show article details.

    Pfizer and BioNTech Provide Update on Omicron Variant

    GlobeNewswire – 6:56 AM ET 12/08/2021

    NEW YORK and MAINZ, Germany, December 8, 2021 — Pfizer Inc. and BioNTech SE (BNTX) today announced results from an initial laboratory study demonstrating that serum antibodies induced by the Pfizer-BioNTech COVID-19 Vaccine neutralize the SARS-CoV-2 Omicron variant after three doses.

  15. Show article details.

    Pfizer and BioNTech Provide Update on Omicron Variant

    Business Wire – 6:54 AM ET 12/08/2021

    NEW YORK & MAINZ, Germany---- Pfizer Inc. (PFE) and BioNTech SE (BNTX) today announced results from an initial laboratory study demonstrating that serum antibodies induced by the Pfizer-BioNTech COVID-19 Vaccine neutralize the SARS-CoV-2 Omicron variant after three doses. This press release features multimedia.

  16. Show article details.

    Pfizer and BioNTech Receive Positive CHMP Opinion for COMIRNATY® in Children 5 to under 12 Years of Age in the European Union

    GlobeNewswire – 7:30 AM ET 11/25/2021

    NEW YORK and MAINZ, Germany, November 25, 2021—Pfizer Inc. and BioNTech SE (BNTX) today announced that the Committee for Medicinal Products for Human Use of the European Medicines Agency issued a positive opinion on the administration of the companies’ COVID-19 vaccine COMIRNATY® in children 5 to under 12 years of age.

  17. Show article details.

    Follow-Up Data from Phase 3 Trial Of Pfizer-BioNTech COVID-19 Vaccine Support Safety and High Efficacy in Adolescents 12 Through 15 Years of Age

    GlobeNewswire – 6:45 AM ET 11/22/2021

    NEW YORK and MAINZ, GERMANY, November 22, 2021 — Pfizer Inc. and BioNTech SE (BNTX) today announced topline results from a longer-term analysis of the safety and efficacy of their COVID-19 vaccine in individuals 12 through 15 years of age.

  18. Show article details.

    Pfizer and BioNTech Receive Expanded U.S. FDA Emergency Use Authorization of COVID-19 Vaccine Booster to Include Individuals 18 and Older

    GlobeNewswire – 8:25 AM ET 11/19/2021

    NEW YORK and MAINZ, Germany, November 18, 2021— Pfizer Inc. and BioNTech SE (BNTX) today announced that the U.S. Food and Drug Administration has expanded the emergency use authorization of a booster dose of the Pfizer-BioNTech COVID-19 Vaccine to include individuals 18 years of age and older.

  19. Show article details.

    Pfizer and BioNTech Receive Expanded U.S. FDA Emergency Use Authorization of COVID-19 Vaccine Booster to Include Individuals 18 and Older

    Business Wire – 8:25 AM ET 11/19/2021

    Pfizer Inc. (PFE) and BioNTech SE (BNTX) today announced that the U.S. Food and Drug Administration has expanded the emergency use authorization of a booster dose of the Pfizer-BioNTech COVID-19 Vaccine to include individuals 18 years of age and older. This press release features multimedia.

  20. Show article details.

    BioNTech Receives FDA Fast Track Designation for its FixVac Candidate BNT111 in Advanced Melanoma

    GlobeNewswire – 6:30 AM ET 11/19/2021

    MAINZ, GERMANY, November 19, 2021 — BioNTech SE (BNTX) today announced that the U.S. Food and Drug Administration granted Fast Track Designation for BNT111, an investigational cancer immunotherapy for the potential treatment of advanced melanoma.

Page:

Today's and Upcoming Events

  • Mar
    30

    BNTX to announce Q4 earnings (Confirmed)

Past Events (last 90 days)

  • Nov
    09

    BNTX announced Q3 earnings.

Data provided by Thomson Reuters © 2022

Technical Events

Technical Analysis

PROVIDED BY TRADING CENTRAL
As with all your investments through Fidelity, you must make your own determination whether an investment is appropriate for you. Fidelity is not recommending or endorsing this security by making it available to customers. You should conduct research and perform a thorough investigation as to the characteristics of any securities you intend to purchase. Before investing, you should read the prospectus, offering circular, indenture, or similar document carefully for a full description of the product, including its features and risks, to determine whether it is an appropriate investment for your investment objectives, risk tolerance, financial situation and other individual factors, and be sure to re-evaluate those factors on a periodic basis.

Performance data shown represents past performance, which is no guarantee of future results. Current performance may be higher or lower than the performance data quoted. Yield and return will vary, therefore, you may have a gain or loss when you sell your shares.


Stock markets are volatile and can decline significantly in response to adverse issuer, political, regulatory, market, or economic developments. Growth stocks can be more volatile than other types of stocks. Value stocks can continue to be undervalued by the market for long periods of time. Foreign securities are subject to interest-rate, currency-exchange-rate, economic, and political risks, all of which are magnified in emerging markets. Illiquidity is an inherent risk associated with investing in real estate and REITs. There is no guarantee the issuer of a REIT will maintain the secondary market for its shares and redemptions may be at a price which is more or less than the original price paid. Closed-end funds can trade at a discount to their NAV. Shareholders of Master Limited Partnerships may be treated as partners for tax purposes. Partnerships issue a Schedule K-1 (Form 1065) rather than a Form 1099 form for tax purposes. It lists the partner's share of income, deductions, credits, etc. Speak with your tax advisor to determine how this may affect you. A royalty trust is a type of corporation, mostly in the United States or Canada, usually involved in oil and gas production or mining. Royalty trusts may have special tax treatment, so you should consult a tax advisor on the potential tax consequences of investing in them.

News, commentary and events are from third-party sources unaffiliated with Fidelity. Fidelity does not endorse or adopt their content. Fidelity makes no guarantees that information supplied is accurate, complete, or timely, and does not provide any warranties regarding results obtained from their use.

Any data, charts and other information provided on this page are intended for research purposes to help self-directed investors evaluate many types of securities including, but not limited to common stocks, American Depository Receipts, Master Limited Partnerships, real estate investment trusts. traditional preferred stock, trust preferred securities, third-party trust certificates, convertible securities, mandatory convertible securities and other exchange-traded equity and/or debt securities. Criteria and inputs entered, including the choice to make security comparisons, are at the sole discretion of the user and are solely for the convenience of the user. Analyst opinions, ratings and reports are provided by third-parties unaffiliated with Fidelity. All information supplied or obtained from this page is for informational purposes only and should not be considered investment advice or guidance, an offer of or a solicitation of an offer to buy or sell a security, or a recommendation or endorsement by Fidelity of any security or investment strategy. Fidelity does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating individual securities. Fidelity makes no guarantees that information supplied is accurate, complete, or timely, and does not provide any warranties regarding results obtained from its use.

462499.6.0
See the Latest Features
Personalized
Get relevant information about your holdings right when you need it.
See Your Performance Click the portfolio icon to get information about stocks you own without leaving the research page.
Faster Access to Positions A shortcut to view the full list of positions in your portfolio? Yes, please! Use the ticker search box.
Add Your Own Notes Use Notebook to save your investment ideas in one convenient, private, and secure place.
Convenient For You
Research that's clear, accessible, and all in one place makes for a better experience.
One-Stop Shop See everything you need to make investment decisions right in the dashboard.
Access Anywhere No matter where you are, use the Stock Research experience across multiple devices.
New Ideas, On the Ready Find new ideas using quick links to the Stock Screener.
New Ways to Research
Discover new tools to add or diversify your existing research strategy.
StockTwits Read live tweets from the financial and investing community about the stock you're interested in.
Fundamental Analysis Save time on research by getting an overall assessment of a company's valuation, quality, growth stability, and financial health.
Recognia Technical Analysis Perfect for the technical trader—this indicator captures a stock's technical events and converts them into short, medium, and long-term sentiment.
Top Competitors See how a stock measures up by instantly comparing it to the industry average and its top four competitors.
Social Sentiment Get a sense of people's overall feelings towards a company in social media with this summary tool.
Earnings Data Monitor earnings expectations over the past three quarters and model a stock's price based on its P/E.